Moderna Stock News

Cathie Wood's ARK Invest funds were unstoppable in 2020 as investors piled into disruptive innovation stocks during the low-rate lockdown environment. After peaking in early 2021, the ARK funds — mo

The Investment Committee gives you their top stocks to watch for the second half.

Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its COVID-19 vaccine, the Financial Times reported on Friday.

Moderna's sales soared into the billions as it conquered the coronavirus vaccine market -- and today the company promises to deliver many new products in the near term. Novavax struggled in recent tim

Moderna's waiting for the FDA to give it a nod for its next potential blockbuster -- an RSV vaccine. But the FDA is taking longer than planned to review the vaccine candidate.

Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.

Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Moderna has a deep pipeline that should help it land brand-new approvals regularly. DexCom has a massive opportunity in the vast continuous glucose monitoring market.

CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Bernstein's 40th Annual Strategic Decisions C

Moderna is using OpenAI's ChatGPT and other tools extensively. In particular, OpenAI's solution is helping with some much-dreaded work.

Moderna (MRNA) shares lost ground in intraday trading Friday as the biotech's effort to move beyond just a COVID-19 vaccine was stalled somewhat by U.S. regulators looking at its new shot to treat res

Moderna Inc.'s stock fell 1.8% early Friday, after the company said the Food and Drug Administration will not complete its review of the company's respiratory syncytial virus, or RSV, vaccine by the o

The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector ha

The U.S. Food and Drug Administration has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine by more than two weeks to the end of this month due to some "administrative co

The FDA has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said.